SHIM
CANF

Stone House Investment Management’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Stone House Investment Management’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24
Closed -$1.03K – 407
2023
Q4 		$1.03K Buy
+24
New +$1.03K ﹤0.01% 297

Other funds holding CANF

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Stone House Investment Management's CANF Position: Q1 2024 in Review

Stone House Investment Management sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q1 2024, closing a stake of 24 shares — an estimated $1.03K sold.

Stone House Investment Management first reported a position in CANF in Q4 2023 and held it in 1 quarter. The position peaked at $1.03K in Q4 2023. 8 funds tracked by Wall St. Rank hold CANF as of Q1 2024.

  • Stone House Investment Management reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Stone House Investment Management sold 24 Can-Fite BioPharma American Depositary Shares shares in Q1 2024, an estimated $1.03K.
  • Stone House Investment Management first reported a position in Can-Fite BioPharma American Depositary Shares in Q4 2023 and held it in 1 quarter.
  • Stone House Investment Management's Can-Fite BioPharma American Depositary Shares position peaked at $1.03K in Q4 2023.
  • 8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2024.

Based on Stone House Investment Management's 13F filing for Q1 2024, filed 15 May 2024.